These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1372811)

  • 1. Phosphodiesterases in vascular endothelial cells.
    Kishi Y; Ashikaga T; Numano F
    Adv Second Messenger Phosphoprotein Res; 1992; 25():201-13. PubMed ID: 1372811
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacological manipulation of tissue cyclic AMP by inhibitors. Effects of phosphodiesterase inhibitors on the functions of platelets and vascular endothelial cells.
    Tani T; Sakurai K; Kimura Y; Ishikawa T; Hidaka H
    Adv Second Messenger Phosphoprotein Res; 1992; 25():215-27. PubMed ID: 1372812
    [No Abstract]   [Full Text] [Related]  

  • 3. Inhibition of neoplastic cell growth by quiescent cells is mediated by serum concentration and cAMP phosphodiesterase inhibitors.
    Bertram JS; Bertram BB; Janik P
    J Cell Biochem; 1982; 18(4):515-38. PubMed ID: 6282911
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparative study of the effects of cyclic nucleotide phosphodiesterase inhibitors on bone resorption and cyclic AMP formation in vitro.
    Lerner U; Ransjö M; Fredholm BB
    Biochem Pharmacol; 1986 Dec; 35(23):4177-89. PubMed ID: 2431692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of the phosphodiesterase regulated by muscarinic cholinergic receptors of 1321N1 human astrocytoma cells.
    Tanner LI; Harden TK; Wells JN; Martin MW
    Mol Pharmacol; 1986 May; 29(5):455-60. PubMed ID: 2422535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the low Km cyclic AMP phosphodiesterase and activation of the cyclic AMP system in vascular smooth muscle by milrinone.
    Silver PJ; Lepore RE; O'Connor B; Lemp BM; Hamel LT; Bentley RG; Harris AL
    J Pharmacol Exp Ther; 1988 Oct; 247(1):34-42. PubMed ID: 2845058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis.
    Netherton SJ; Maurice DH
    Mol Pharmacol; 2005 Jan; 67(1):263-72. PubMed ID: 15475573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP: role in vasodilatation.
    Lugnier C; Komas N
    Eur Heart J; 1993 Nov; 14 Suppl I():141-8. PubMed ID: 8293765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro vascular relaxation by new inotropic agents: relationship to phosphodiesterase inhibition and cyclic nucleotides.
    Kauffman RF; Schenck KW; Utterback BG; Crowe VG; Cohen ML
    J Pharmacol Exp Ther; 1987 Sep; 242(3):864-72. PubMed ID: 2821228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory mechanisms of particulate cyclic nucleotide phosphodiesterases.
    Thompson WJ; Lavis VR; Whalin ME; Strada SJ
    Adv Second Messenger Phosphoprotein Res; 1992; 25():165-84. PubMed ID: 1313258
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapeutic potential of isozyme-selective phosphodiesterase inhibitors in the treatment of asthma.
    Torphy TJ; Livi GP; Balcarek JM; White JR; Chilton FH; Undem BJ
    Adv Second Messenger Phosphoprotein Res; 1992; 25():289-305. PubMed ID: 1372813
    [No Abstract]   [Full Text] [Related]  

  • 12. Initial biochemical and functional characterization of cyclic nucleotide phosphodiesterase isozymes in canine colonic smooth muscle.
    Barnette MS; Manning CD; Price WJ; Barone FC
    J Pharmacol Exp Ther; 1993 Feb; 264(2):801-12. PubMed ID: 7679736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of chemotactic peptide-induced neutrophil adhesion to vascular endothelium by cAMP modulators.
    Derian CK; Santulli RJ; Rao PE; Solomon HF; Barrett JA
    J Immunol; 1995 Jan; 154(1):308-17. PubMed ID: 7995950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential inhibition of cyclic AMP and cyclic GMP hydrolysis in rat renal cortex.
    Zenser TV; Craven PA; DeRubertis FR; Davis BB
    Arch Biochem Biophys; 1977 Jan; 178(2):598-606. PubMed ID: 189700
    [No Abstract]   [Full Text] [Related]  

  • 15. Insulin activation of cyclic AMP phosphodiesterase in intact ureteral segments.
    Weiss RM; Wheeler MA
    J Pharmacol Exp Ther; 1988 Nov; 247(2):630-4. PubMed ID: 2846825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Separation of multiple forms of cyclic nucleotide phosphodiesterase from hog heart.
    Nasu S
    Bull Osaka Med Sch; 1976 Oct; 22(2):51-68. PubMed ID: 203355
    [No Abstract]   [Full Text] [Related]  

  • 17. Inhibitory effect of NZ-105, a 1,4-dihydropyridine derivative, on cyclic nucleotide phosphodiesterase activity.
    Yamashita T; Masuda Y; Sakai T; Tanaka S; Kasuya Y
    J Pharm Pharmacol; 1993 Jun; 45(6):530-4. PubMed ID: 7689649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of cyclic nucleotide phosphodiesterase isoforms from rat heart and bovine aorta. Separation and inhibition by selective reference phosphodiesterase inhibitors.
    Prigent AF; Fougier S; Nemoz G; Anker G; Pacheco H; Lugnier C; Lebec A; Stoclet JC
    Biochem Pharmacol; 1988 Oct; 37(19):3671-81. PubMed ID: 2845994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of both cyclic [3H]AMP and cyclic [3H]GMP in cultured vascular smooth muscle cells labeled with [3H]hypoxanthine: use in studies of cardiovascular drugs.
    Maurice DH; Lee RM; Haslam RJ
    Anal Biochem; 1993 Nov; 215(1):110-7. PubMed ID: 8297002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphodiesterases in the rat renal vasculature.
    Jackson EK; Mi Z; Carcillo JA; Gillespie DG; Dubey RK
    J Cardiovasc Pharmacol; 1997 Dec; 30(6):798-801. PubMed ID: 9436820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.